Vistagen completes patient enrollment in Phase 3 social anxiety trial for fasedienol

Vistagen Therapeutics announced completion of patient follow-up in PALISADE-4, its Phase 3 clinical trial evaluating fasedienol nasal spray as an acute treatment for social anxiety disorder. The last patient has finished their final visit in the randomized, double-blind, placebo-controlled portion of the study, marking a critical milestone in the drug's development path.

For retail investors, this completion is significant because it positions Vistagen to analyze trial data and potentially move toward a New Drug Application (NDA) submission to the FDA. Success in this trial could open a substantial market opportunity in social anxiety treatment, where acute-use nasal spray options are limited.

The company's ability to demonstrate efficacy versus placebo will determine whether fasedienol can advance to commercialization. Investors should watch for top-line data readout from PALISADE-4, expected in the coming months. The trial results will reveal whether fasedienol met its primary endpoints and will directly impact the company's regulatory and commercial prospects.